Stephen L. Hauser

Pathology and Forensic Medicine · 2006–2020

A researcher in the Science corpus: 15 papers; trusts 3 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

• Pathology and Forensic Medicine — 74 citations into it
• Neurology — 43 citations into it
• Rheumatology — 28 citations into it

Whom Stephen L. Hauser trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. Christian Confavreux
2. Sandra Vukusic
3. Michael Barnett
4. Hans Lassmann

Who trusts Stephen L. Hauser overall

1. Hans Lassmann
2. F. Mackay

Papers from Stephen L. Hauser's perspective

Ordered by how strongly the researchers Stephen L. Hauser trusts endorse each paper. Same corpus, a different order for every researcher.

1. Multiple Sclerosis (Journal - Michigan State Medical Society)
2. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. (American Journal of Pathology)
3. NG2-Positive Oligodendrocyte Progenitor Cells in Adult Human Brain and Multiple Sclerosis Lesions (Journal of Neuroscience)
4. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. (Brain : a journal of neurology)
5. Neurological disability correlates with spinal cord axonal loss and reduced N‐acetyl aspartate in chronic multiple sclerosis patients (Annals of Neurology)
6. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. (New England Journal of Medicine)
7. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
8. Common SNPs explain a large proportion of heritability for human height (Nature Genetics)
9. Genome-partitioning of genetic variation for complex traits using common SNPs (Nature Genetics)
10. Biological interpretation of genome-wide association studies using predicted gene functions (Nature Communications)

Their papers

• Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci (2009) — 835 citations
• Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models (2017) — 901 citations
• Treatment of Multiple Sclerosis: A Review. (2020) — 788 citations
• Multiple Sclerosis Genomic Map implicates peripheral immune cells & microglia in susceptibility (2019) — 1,186 citations
• Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis (2017) — 1,605 citations
• Ocrelizumab versus Interferon Beta‐1a in Relapsing Multiple Sclerosis (2017) — 1,645 citations
• Class II HLA interactions modulate genetic risk for multiple sclerosis (2015) — 366 citations
• Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis (2011) — 2,780 citations
• Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. (2011) — 1,159 citations
• Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. (2011) — 700 citations
• Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double‐blind placebo‐controlled multicenter trial (2009) — 908 citations
• B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. (2008) — 1,321 citations
• Risk alleles for multiple sclerosis identified by a genomewide study. (2007) — 1,623 citations
• Interleukin 7 receptor α chain ( IL7R ) shows allelic and functional association with multiple sclerosis (2007) — 693 citations
• The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. (2006) — 805 citations